Timothy C. Dec Acquires 65,000 Shares of OpGen, Inc. (NASDAQ:OPGN) Stock
OpGen, Inc. (NASDAQ:OPGN) CFO Timothy C. Dec acquired 65,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The stock was bought at an average cost of $0.40 per share, with a total value of $26,000.00. Following the purchase, the chief financial officer now owns 118,966 shares in the company, valued at $47,586.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
OpGen, Inc. (NASDAQ OPGN) traded down 1.016% during midday trading on Tuesday, hitting $0.302. 2,633,783 shares of the stock traded hands. The stock’s 50-day moving average price is $0.70 and its 200 day moving average price is $1.00. The company’s market capitalization is $8.27 million. OpGen, Inc. has a 52 week low of $0.29 and a 52 week high of $4.65.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/18/timothy-c-dec-acquires-65000-shares-of-opgen-inc-nasdaqopgn-stock.html.
Several brokerages recently commented on OPGN. Zacks Investment Research downgraded shares of OpGen from a “buy” rating to a “sell” rating in a research note on Tuesday, May 2nd. Dawson James restated a “buy” rating on shares of OpGen in a research report on Monday, June 19th. Finally, HC Wainwright set a $1.00 price target on shares of OpGen and gave the company a “buy” rating in a research report on Tuesday.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.